HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea

Clinical Infectious Diseases

Volumn 54, Issue 8, 2012, Pages 1204-1211

  Campbell, James D ^a   Moore, David ^b,c   Degerman, Richard ^d   Kaharuza, Frank ^d   Were, Willy ^d   Muramuzi, Emmy ^d   Odongo, George ^d   Wetaka, Milton ^d   Mermin, Jonathan ^a   Tappero, Jordan W ^d  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; ENDEMIC DISEASE; FEMALE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOME CARE; HOUSEHOLD; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALARIA; MALE; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; RANDOM SAMPLE; RANDOMIZATION; RISK FACTOR; SINGLE BLIND PROCEDURE; UGANDA; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHEMOPREVENTION; DIARRHEA; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALARIA; MALE; RISK ASSESSMENT; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UGANDA; WITHHOLDING TREATMENT;

EID: 84859097222     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis013     Document Type: Article

References (14)

1. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
2. Uganda Ministry of Health. National Policy Guidelines for Cotrimoxazole prophylaxis for people with HIV/AIDS. Kampala: Ministry of Health, 2005.
3. Ministry of Health (MOH) Kampala. National antiretroviral treatment and care guidelines for adults and children. Kampala, Uganda: Ministry of Health, 2003. Available at: http://collections.infocollections.org/whocountry/en/d/ Jh4325e/14.html. Accessed 02 February 2012.
4. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents, and adults in resource limited settings. Geneva, Switzerland: World Health Organization, 2006.
5. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322:161-5.
6. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virusinfected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178:1126-32.
7. Kaplan JE, Hanson DL, Jones JL, Dworkin MS. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS 2001; 15:1831-6.
8. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155:60-6.
9. Trikalinos TA, Ioannidis JP. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. Clin Infect Dis 2001; 33:1901-9.
10. Wiktor SZ, Sassan MM, Grant AD, et al. Efficacy of trimethoprim- sulphamethoxazole prophylaxis to decreasemorbidity andmortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353:1469-75.
11. Mermin J, Lule J, Ekwaru JP, et al. Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and HIV viral load among persons with HIV in rural Uganda. Lancet 2004; 364: 1428-34.
12. Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356:1051-6.
13. Mockenhaupt FP, Reither K, Zanger P, et al. Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob Agents Chemother 2007; 51:3273-81.
14. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365:233-40.